Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €59.00 ($68.60) price objective by equities researchers at Jefferies Financial Group in a research note issued on Tuesday, September 25th. The firm presently has a “neutral” rating on the stock. Jefferies Financial Group’s target price points to a potential downside of 10.98% from the stock’s previous close.

FRE has been the topic of a number of other research reports. Commerzbank set a €83.00 ($96.51) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Tuesday, September 11th. Oddo Bhf set a €82.00 ($95.35) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Wednesday, August 1st. Berenberg Bank set a €81.85 ($95.17) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Monday, June 18th. Barclays set a €80.00 ($93.02) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Thursday, August 16th. Finally, Deutsche Bank set a €84.00 ($97.67) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Tuesday, June 19th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have assigned a buy rating to the company. Fresenius SE & Co KGaA has an average rating of “Buy” and an average target price of €77.79 ($90.46).

Shares of Fresenius SE & Co KGaA stock traded down €1.50 ($1.74) during trading on Tuesday, hitting €66.28 ($77.07). The company’s stock had a trading volume of 1,713,451 shares. Fresenius SE & Co KGaA has a 52 week low of €60.16 ($69.95) and a 52 week high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Featured Story: What is the Ex-Dividend Date in Investing?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.